Tag: Acarix

Acarix signs additional commercial agreement in US and receives rapid orders in both Mississippi and Tennessee

Coronary/Structural Heart by 0 comments

Acarix today announces an additional commercial partnership in the US covering the states of Tennessee, Kentucky, Mississippi, and Alabama. The new partnership with Ancillary Care Services LLC has led to rapid orders and use of the CADScor® System by regional and rural clinics to enable accessible, rapid and cost-effective rule out of coronary artery disease. The US states of Tennessee, Kentucky, Mississippi, and Alabama have among the highest prevalence rates for heart disease in the country. Reasons include higher […]

Continue Reading →

Acarix receives strategic order for the CADScor®System in US

Coronary/Structural Heart by 0 comments

Acarix today announces first order of the CADScor®System in the US from Apex Heart and Vascular Center led by renowned cardiologist Dr. Anuj Shah. The CADScor®System will used at the New Jersey-based APEX clinics for rapid AI-based diagnostics of patients with chest pain. “I’m excited about bringing the CADScor®System to our APEX clinics and evaluating […]

Continue Reading →

Correction of press release: Acarix AB (publ) publishes Year-End Report 2021

Financial by 0 comments

Press release  Malmö, Sweden, February 17, 2022 Correction of press release: Acarix AB (publ) publishes Year-End Report 2021 The press release published today at 08.00 CET did not include the quarterly report. The quarterly report is included in the press release below, which otherwise correspond to the previously published press release. For more information contact: Christian Lindholm, CFO, phone +46 705 118333, […]

Continue Reading →

Acarix submits breakthrough designation request with FDA for heart failure diagnosis

Coronary/Structural Heart Regulatory by 0 comments

Malmö, Sweden, February 9, 2022 Acarix submits breakthrough designation request with FDA for heart failure diagnosis  Acarix expands its portfolio and submits a breakthrough designation request for its innovative technology for heart failure diagnosis with the Food and Drug Administration (FDA) in USA. Heart failure affects more than 6 million people in the USA at costs exceeding $30 billion per […]

Continue Reading →

Acarix carries out a directed issue of shares to guarantors in conjunction with completed rights issue

Financial by 0 comments

Acarix AB (”Acarix” or the “Company”) has, as previously announced, completed the rights issue of shares amounting to approximately SEK 79.3 million (the ”Rights Issue”), which was announced on 5 November 2021 and the outcome of the Rights Issue was announced on 20 December 2021. In connection herewith, the board of directors of Acarix has, […]

Continue Reading →

Proximo Medical Named Commercialization Partner for Acarix

Coronary/Structural Heart by 0 comments

LONGMONT, Colo., Nov. 18, 2021 /PRNewswire/ — Proximo Medical, LLC, a business acceleration solution that addresses medical device commercialization challenges among startup and established medical device technologies looking to expand adoption in the U.S., today announced a partnership with Acarix, a Swedish medical device company that provides innovative  solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The […]

Continue Reading →

Acarix accelerates US market entry with Proximo Medical as commercialization partner

Coronary/Structural Heart by 0 comments

Press release (MAR) Malmö, Sweden, November 9, 2021 Acarix accelerates US market entry with Proximo Medical as commercialization partner Acarix today announced the signing of a Commercial Access agreement with Proximo Medical, LLC, to rapidly initiate the commercialization of the CADScor system in the US market. With the agreement, Acarix immediately gains market access and a senior […]

Continue Reading →
1 2 3 4 5